If you have been reading about ICP-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-26. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| INCI name | Copper tripeptide-1 | Standard designation on cosmetic ingredient labels |
| Peptide sequence | Gly-His-Lys | Three-residue ligand; binding occurs at the histidine side chain |
| Metal-to-peptide ratio | 1 to 1 | One copper(II) ion per peptide unit |
| Appearance | Blue to violet powder | Colour arises from copper-to-peptide electronic transitions |
| Water solubility | Freely soluble | Commonly formulated in aqueous or water-alcohol systems |
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
Solutions of GHK-Cu respond strongly to pH, redox conditions, and the presence of competing chelators such as EDTA. Below roughly pH 4 the copper tends to dissociate, because the amide nitrogen donors become protonated and can no longer coordinate. Strongly alkaline conditions instead favour hydrolysis and precipitation of copper hydroxide. Dissolved oxygen and light accelerate breakdown of the peptide backbone, and the copper released during that process can catalyse further oxidation, so dry, cold, dark storage is the usual recommendation.
Routine characterisation relies on reversed-phase high-performance liquid chromatography for peptide purity, paired with mass spectrometry for identity confirmation. Ultraviolet-visible spectroscopy detects the metal centre through its absorption band in the visible region, and inductively coupled plasma mass spectrometry quantifies total copper so that a metal-to-peptide ratio can be calculated. Amino acid analysis confirms the expected residue composition. Together these techniques establish concentration, identity, and stoichiometry, but none of them directly reports biological activity.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
== History == MDDMA was first described in the scientific literature by Alexander Shulgin and colleagues by 1980. Subsequently, it was described in greater detail by Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991. The drug was described as a possible novel designer drug in 2025. David E. Olson and colleagues characterized (R)-MDDMA as a non-hallucinogenic psychoplastogen with antidepressant-like effects and improved safety relative to MDMA in 2026.
which introduced the world's first umami seasoning: monosodium glutamate (MSG), marketed in Japan under the name "Ajinomoto." MSG subsequently spread worldwide as a seasoning capable of enhancing umami in a wide variety of dishes. In 2000, researchers at the University of Miami identified the presence of umami receptors on the tongue, and in 2006, Ajinomoto's research laboratories found similar receptors in the stomach.
== Characteristics == Changes, mostly seen as advances, in all areas of human activity—politics, industry, society, economics, commerce, transport, communication, mechanization, automation, science, medicine, technology, religion, the arts, and other aspects of culture—appear to have transformed an Old World into the Modern or New World. In each case, the identification of the change over time can be used to demarcate the old and old-fashioned from the modern. Starting in western countries, the modern world has seen a systematic re-evaluation of value systems, monarchical regimes, and feudal economic systems. These have often been replaced by democratic and liberal ideas in the areas of politics, science, psychology, sociology, and economics. Some events of modern history, though born out of context not entirely new, show a new way of perceiving the world. The concept of modernity interprets the general meaning of these events and seeks explanations for major developments. Historians analyze the events taking place in Modern Times, since the so-called "Middle Ages" (between Modern and Ancient Times).
Sources: en.wikipedia.org
=== Dextran nanoparticle applications === Dextran nanoparticles have advantages such as increased drug-loading capacity, improved cellular uptake, reduce off-site toxicity, and increase local drug concentrations at the target tissue site. The current research indicates that dextran nanoparticles can potentially have applications in the delivery of anti-tumor therapeutics.
In January 2023, Vice President Geraldo Alckmin met with Vice President Frans Timmermans of the EU Commission in Brasília. During his visit to Brazil, Timmermans said that President Lula's efforts to end destruction in the Amazon deserves support and cooperation from the European Union, adding that the EU could donate up to €750,000 to help the Yanomami people facing a humanitarian crisis. In March 2023, the EU's commissioner for competition Margrethe Vestager met with Vice President Alckmin and other Brazilian officials during a meeting in Brasília to unveil the EU-Brazil bilateral Investment Map. In June 2023, Lula met with EU president Ursula von der Leyen to discuss areas such as environment, science and technology and trade, namely the EU-Mercosur trade deal. Lula expressed concerns over a European Union's side letter proposal of sanctioning Mercosur goods in case they fail to meet environmental goals saying that "between partners there should be mutual confidence not mistrust and sanctions" and that the sanctions could hurt genuine Brazilian green efforts. During the meeting the European Union pledged to donate 20 million euros to the Amazon Fund. In July 2023, numerous Latin American, Caribbean and European leaders, including Lula, attended the III EU-CELAC summit in Brussels to discuss topics such as global hunger, inequalities, poverty and climate change. On the sidelines of the summit, Lula made the case for the EU-Mercosur trade deal and expressed concern for protectionist policies in the agreement.
=== Off-label drugs === α2-Adrenergic receptor agonists (e.g., clonidine, dexmedetomidine, guanfacine) – opioid withdrawal Benzodiazepines (e.g., diazepam) – GABAA receptor positive allosteric modulators – alcohol withdrawal syndrome Gabapentinoids (e.g., gabapentin, pregabalin) – α2δ subunit-containing voltage-gated calcium channel blockers – alcohol withdrawal syndrome Ibogaine (Tabernanthe iboga) – various actions, oneirogen/hallucinogen – opioid use disorder Lobeline – nicotinic acetylcholine receptor agonist – smoking withdrawal Mecamylamine – nicotinic acetylcholine receptor antagonist – smoking withdrawal Nicotine (nicotine replacement therapy; e.g., nicotine gum, nicotine inhaler, nicotine lozenge, nicotine nasal spray, nicotine patch) – nicotinic acetylcholine receptor agonist – smoking withdrawal Phenibut (Anvifen) – GABAB receptor agonist and gabapentinoid (α2δ subunit-containing voltage-gated calcium channel blocker) – alcoholism and alcohol withdrawal syndrome Serotonergic psychedelics (e.g., psilocybin, LSD, mescaline, DMT) – serotonin 5-HT2A receptor agonists and psychedelic hallucinogens – various substance use disorders Topiramate (Topamax) – various actions – alcoholism and alcohol withdrawal syndrome
Sources: en.wikipedia.org
It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.
The free peptide was reported in 1973 by Loren Pickart, who isolated it from human plasma. Its copper-binding behaviour was characterised over the following years. The metal-bound form has been the subject of most later research.
Yes. Copper tripeptide-1 is the name used in cosmetic ingredient labelling, while GHK-Cu is the shorthand found in the scientific literature. Both refer to the same peptide-copper complex, and the two terms are interchangeable in most technical documents.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.